602 - Minimally Invasive Treatment of Aneurysmal Bone Cysts with Gelified Ethanol (DiscoGel): Evaluation of Feasibility,Safety, and Efficacy

Monday, April 13, 2026

12:10 PM - 1:10 PM ET

Poster Presenter(s)

SG

Sylvain Grange, MD, PhD

Interventional Radiologist
Department of Radiology, University Hospital of Saint-Etienne, Faculty of Medicine, Jean Monnet University, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Saint-Etienne, France, France

Author/Co-author(s)

VG

Valentin Gineys, MD

Radiologist
Department of Radiology, University Hospital of Saint Etienne, Avenue Albert Raymond, 42055 Saint-Priest-en-Jarez, Saint-Etienne Cedex 2, France, France
NS

Nicolas Stacoffe, MD

Interventionnal Radiologist
Department of Radiology, Groupement Hospitalier Sud, Hospice Civils de Lyon, Pierre-Bénite, France, France
SB

Sylvain Bertholon, MD

Radiologist
Department of Radiology, University Hospital of Saint Etienne, Avenue Albert Raymond, 42055 Saint-Priest-en-Jarez, Saint-Etienne Cedex 2, France, France
HA

Hassan Al Khoury Salem, MD

Surgeon
Department of Pediatric Surgery, University Hospital of Saint Etienne, Avenue Albert Raymond, 42055 Saint-Etienne Cedex 2, France, France
EH

Elie Haddad, MD

Surgeon
Department of Pediatric Surgery, University Hospital of Saint Etienne, Avenue Albert Raymond, 42055 Saint-Etienne Cedex 2, France, France
CB

Claire Boutet, MD, PhD

Radiologist
CHU de Saint-Etienne, Service ´ de Radiologie, TAPE Research Unit EA 7423, Saint-Etienne, France, France
RG

Rémi Grange, MD

Interventional Radiologist
CHU Saint-Etienne, Service de Radiologie, Saint-Etienne, France; Universite Jean Monnet Saint-Etienne, France, France

Purpose: The aim of this study was to evaluate safety and effectiveness of radio-opaque gelified ethanol sclerotherapy in treating primary aneurysmal bone cyst

Materials and Methods: In this single-center, retrospective study (January 1st, 2012, to June 30th, 2024), 32 patients with primary aneurysmal bone cysts were treated with percutaneous sclerotherapy using radio-opaque gelified ethanol at various skeletal sites. Of these, 27 patients were included in the analysis, 5 patients were excluded due to follow-up of less than 12 months. The primary outcome measure was the safety of the procedures. Secondary outcomes measures included clinical success, defined as the absence of post-sclerotherapy fractures or the need for surgical revision, and radiological success, determined by the conversion of an active or aggressive aneurysmal bone cyst to inactive, according to Campanacci’s classification.

Results: No major complications related to the procedure were observed. One minor complication (3.7%) was reported: One local collection resolved with antibiotic therapy. The remaining patients showed favorable clinical and radiological outcomes. No fractures were recorded

after sclerotherapy. Surgical revision for progressive recurrence was necessary in 2 cases (7.4%). Aneurysmal bone cyst becoming inactive in 21 of 27 (77.8%) patients after 12 months, 13 of 14 (92.8%) patients after 24 months, and 7 of 7 (100%) and 5 of 5 (100%) patients after more than 36 and 48 months, respectively.

Conclusion: Radio-opaque gelified ethanol sclerotherapy offers a safe, effective, and minimally invasive treatment for primary aneurysmal bone cyst. It may be considered a first-line approach, similar to other sclerotherapy methods, potentially avoiding the need for invasive surgery as an initial treatment option